Ticagrelor is a reversible, direct-acting P2Y₁₂ receptor antagonist indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) and coronary artery disease. As the first agent in its class that does not require metabolic activation, Ticagrelor provides rapid onset and offset of platelet inhibition, with 100% inhibition of platelet aggregation achieved at therapeutic doses. Ticagrelor and its major active metabolite, AR-C124910XX, are approximately equipotent and together contribute to the drug's antiplatelet effect. Ticagrelor and its related impurities—including AR-C124910XX, AR-C133913XX, and various metabolites—serve as critical reference standards for analytical method development, method validation (AMV), and quality control (QC) in ANDA filings.
|
Parameter |
Specification |
|
Product Name |
Ticagrelor |
|
CAS Number |
274693-27-5 |
|
Molecular Formula |
C₂₃H₂₈F₂N₆O₄S |
|
Molecular Weight |
|
|
Appearance |
White to off-white solid |
|
Solubility |
Soluble in DMSO |
|
Storage Condition |
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
Ticagrelor is an oral, reversible, fast-acting P2Y12 receptor antagonist that exerts therapeutic effects by inhibiting platelet activation.
Ticagrelor is a platelet aggregation inhibitor that can be used to prevent stroke and myocardial infarction in patients with acute coronary syndrome. As a non-prodrug, it takes effect directly without metabolic activation by the liver, and binds reversibly to the P2Y12 ADP receptor. Research results show that 12-month treatment with ticagrelor, without increasing major bleeding, further significantly reduces the risk of the composite endpoint of cardiovascular death/myocardial infarction/stroke in patients with acute coronary syndrome (ACS) by 16% compared with clopidogrel, and significantly reduces cardiovascular death by 21% at the same time.
The most commonly reported adverse reactions are dyspnea, contusion and epistaxis; other common adverse reactions are: gastrointestinal bleeding, subcutaneous or dermal bleeding, ecchymosis, and bleeding at the operation site.
Need Ticagrelor for your antiplatelet API manufacturing, impurity profiling, or cardiovascular research? Cosperpharm is your trusted partner for high-quality P2Y₁₂ receptor antagonist intermediates and reference standards. Reach out to our team today—we're ready to support your project from R&D to commercial production.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
